Management of Post-Stroke Memory Impairment

Initial Assessment and Screening

The American Heart Association recommends screening for reversible causes of cognitive impairment, including thyroid-stimulating hormone and vitamin B12 levels, in patients with post-stroke memory deficits 1
Patients should be assessed for electrolyte imbalances, liver and renal function, and screened for infection, constipation, and pain, as these conditions can worsen cognitive symptoms 1
A review of medications, particularly sedating and anticholinergic agents, is necessary to identify potential contributors to cognitive impairment 1
Evaluation for mood disorders, sleep disorders, and hearing/vision impairments is crucial, as these conditions can mimic or exacerbate cognitive symptoms 1

The American Psychological Association recommends screening all patients for post-stroke depression using a validated depression screening tool, as it affects 25-75% of stroke survivors and often presents with cognitive symptoms 3, 2
Depression-related cognitive symptoms may resolve with treatment of depression, making this distinction critical 1
Risk factors for post-stroke depression include higher physical disability, prestroke history of depression/anxiety/cognitive impairment, and lack of social support 1

The American Stroke Association recommends providing training to develop compensatory strategies, which has good evidence supporting its use, for patients with mild short-term memory deficits (Level B Evidence) 3, 2
Target patients who have mild impairments, are fairly independent in daily function, actively identify their memory problems, and are motivated to incorporate strategies 2
Errorless learning techniques can be used for individuals with severe memory deficits 4

The American Psychiatric Association recommends treating depression with selective serotonin reuptake inhibitors (SSRIs) as first-line pharmacotherapy (Level A evidence), as treatment can greatly improve rehabilitation outcomes 3, 2
SSRIs are preferred over tricyclic antidepressants in older patients due to high incidence of anticholinergic effects with tricyclics 3

The American Academy of Neurology recommends not using amphetamines for stroke recovery, based on negative large clinical trials and lack of documented long-term benefits 3
Limited data support use of other neurotransmitter-releasing agents, including methylphenidate 3

Stroke location (left frontotemporal region, left thalamus, right parietal lobe, left middle cerebral artery territory) increases likelihood of post-stroke cognitive impairment 1